KR20100000026A - Composition for improving a atopy epidermal inflammation using pig placenta - Google Patents

Abstract

The present invention relates to a composition for improving atopic dermatitis comprising a pig placenta extract. Specifically, the present invention relates to a composition for improving atopic dermatitis using a pig placenta extract obtained by pulverization by ultrasound and an extract obtained by a solvent extraction method.

Description

Composition for Improving Atopy Epidermal Inflammation Using Pig Placenta}

The present invention relates to a composition for improving atopic dermatitis using pig placenta extract. Specifically, the present invention relates to a composition for improving atopic dermatitis using a pig placenta extract obtained by pulverization by ultrasound and an extract obtained by a solvent extraction method.

The word atopy is derived from the word "atopia" which means "weird" or "inappropriate" in the etymology, which means "clinical hypersensitivity" or "allergy" in dictionary.

Atopic dermatitis causes anaphylactic shock, urticaria and angioedema, wheezing within minutes to hours when exposed to protein antigens such as house dust, mites, animal hair, pollen, and foods commonly found in the environment. (喘 鳴) and shortness of breath, nasal congestion, runny nose, sneezing, conjunctival hyperemia and edema, vomiting, diarrhea, abdominal pain.

In general, atopic dermatitis is characterized by a relatively characteristic skin lesion and distribution according to the age of the patient can be divided into infantile atopic dermatitis, pediatric atopic dermatitis and adult atopic dermatitis. In infancy (infant type) from 2 to 3 months of age when atopic dermatitis begins, infants with atopic dermatitis are red, moist, oily, and crusty on the head, face, and trunk. appear. Childhood (pediatric) after 3 years of age and before puberty not only shows dry skin lesions such as papules, lichenification, scale, and pigmentation on the sides of the arms, legs, wrists, and ankles. Symptoms include, for example, the formation of lichens on the forehead, redness and tearing around the eyes, and cracking and peeling of the skin of the ear. In puberty and adulthood (gender), lesions such as papules, scales, pigmentation, thyroiditis, and nodules appear in the head, face, neck, torso, limbs and limbs. The symptoms of atopic dermatitis usually improve with age, but may continue to be severe until adulthood.

Currently, steroidal drugs widely used as a treatment for atopic dermatitis have an excellent anti-inflammatory effect and immunosuppressive effect, but after long-term use, they have hairy and atrophy skin on the right area, less skin pigment, and thinner skin. Causes

Recently, in order to minimize side effects of existing chemicals, efforts have been made to find natural extracts effective for atopic dermatitis. As such natural extracts, the extract of Felinus linteus mycelium and Chunma disclosed in Korean Patent No. 0825070, Korea Mung bean extract and Gosam extract, which are disclosed in Korean Patent No. 0816266, and Yangje Geun Extract, which are disclosed in Korean Patent No. 0742189.

The present invention also discloses a natural extract having an atopic dermatitis improving effect.

The present invention is to provide a composition for improving atopic dermatitis using pig placenta extract.

Specific aspects or other objects of the present invention will be presented below.

The present invention relates to a composition for improving atopic dermatitis comprising a pig placenta extract as an active ingredient.

The inventors of the present invention, as confirmed in the Examples and Experimental Examples below, in the hexane fraction extract of the pig placenta extract by ultrasound, water, ethanol or a mixed solvent thereof and water, ethanol or a mixed solvent thereof Ethyl acetate fraction extract of pig placenta extract was prepared and evaluated whether the extracts had an effect of improving atopic dermatitis through an in vitro test and a clinical trial.

In vitro test, using the HaCaT cells, a human keratinocyte cell line, pig placenta extract of the present invention is known to increase its expression in patients with atopic dermatitis (macrophage-derived chemokine) and TARC (thymusand activation-regulated chemokine) (( Y. Shimada et al., J. Dermatol. Sci., 34, 201-208, 2004; this document is considered part of this specification).

When administration of cyclosporin A or corticosteroids used as atopic dermatitis treatment agents to atopic dermatitis patients, serum concentrations of MDC and TARC have been reported (Hijnen et. Al., J. Allergy Clin. Immunol .. 113 (2) 334-340; this document is considered part of this specification). In vitro experiments resulted in high expression of MDC and TARC upon treatment of hIFN-γ or TNF-α in HaCaT cells. It has been suggested that a substance that can be used as a therapeutic agent for atopic dermatitis (Horikawa et. Al., Int. Immunol., 14 (7) 767-773, 2002; this document is considered part of this specification).

Porcine placenta extract of the present invention all inhibited the expression of MDC and TARC in HaCaT cells treated with hIFN-γ, in particular, the highest inhibitory effect of the pig placenta extract by ultrasound.

The present inventors prepared the cosmetic composition by mixing with the usual components used in cosmetic preparations having the ultrasound placenta extract by ultrasound having the highest inhibitory effect of the MDC and TARC expression, and then with the cosmetic composition 12 atopic dermatitis Clinical trials were conducted on the patients, which showed a clear improvement in atopy.

The present invention is provided based on these experimental results.

Therefore, the composition for improving atopic dermatitis of the present invention is an active ingredient (a) porcine placenta extract by ultrasound, (b) hexane fraction extract of porcine placenta extract by water, ethanol or a mixed solvent thereof, or (c) water, Ethyl acetate fraction extract of pig placenta extract by ethanol or a mixed solvent thereof.

The following terms have the meanings defined below.

<1> atopic dermatitis

Atopic dermatitis is generally classified into juvenile atopic dermatitis, juvenile atopic dermatitis and adult atopic dermatitis according to the time of its onset or the subject of the invention. Atopic dermatitis is defined herein as including all these types of atopic dermatitis.

<2> placenta

The placenta is generally formed from tissues derived from the fetus and the mother. The placenta is composed of the decidual membrane derived from the uterine mucosa of the mother and the chorion and amniotic membrane derived from the fertilized egg, and refers to the organ where the material exchange between the fetus and the mother occurs.

Porcine placenta as an extraction subject in the present invention will usually be washed and then lyophilized.

<2> Porcine Placenta Extract by Ultrasound

It means that the placenta is crushed by adding water, ethanol or a mixed solvent thereof to the lyophilized and powdered porcine placenta powder, and radiating ultrasonic waves. Refers to an extract in powder form from which the solvent is removed. More preferably, the placenta is crushed and the crushed material is centrifuged to discard the precipitate, and the extract of the supernatant obtained by removing the solvent from the supernatant or lyophilization method, or the placenta, or the placenta is filtered After removal of the extraction residue by centrifugation of the filtrate to discard the precipitate refers to the extract of the supernatant obtained, or powdered extract from which the solvent was removed from the supernatant by a method such as lyophilization. Preferably what is obtained by the process of the following Example and its process conditions.

<3> Hexane Fraction Extract of Porcine Placenta Extract with Water, Ethanol or Mixed Solvents thereof

Extracted by adding water, ethanol or a mixed solvent thereof to lyophilized and powdered porcine placenta powder, and then extracting the solvent by lyophilization, etc., fractions of the hexane layer obtained by adding water and hexane to the crude extract. Refers to a fraction extract obtained by removing hexane as an extract or fraction solvent. Preferably the extract obtained by the process and process conditions of the following examples.

<4> Ethyl Acetate Fraction Extract of Porcine Placenta Extract with Water, Ethanol or Mixed Solvents thereof

Ethyl acetate layer obtained by adding water, ethanol or a mixed solvent thereof to the lyophilized and powdered pig placenta powder, and then extracting the solvent by lyophilization and then adding water and ethyl acetate to the crude extract. It refers to the fraction extract obtained by removing the fractional extract or fractional solvent of ethyl acetate. Preferably, it is extracted by adding water, ethanol or a mixed solvent to the lyophilized and powdered pig placenta powder, and then lyophilizing. It refers to the fraction extract obtained by removing the fraction extract of the ethyl acetate layer or ethyl acetate which is obtained by adding ethyl acetate to the water layer obtained by adding water and hexane to the crude extract obtained by removing an extraction solvent, and standing still. Most preferably refers to the extract obtained by the process and process conditions of the following examples.

<5> improvement

Improvement herein is meant to include alleviation of symptoms, prevention and / or treatment.

<6> active ingredients

An active ingredient refers to an ingredient which shows activity alone or in itself, together with an inactive adjuvant (carrier).

On the other hand, the composition for improving atopic dermatitis of the present invention may include a pig placenta extract as an active ingredient in any amount (effective amount) as long as it can exhibit an atopic dermatitis improvement effect depending on the use, formulation, formulation purpose, etc. It will be determined within the range of 0.001% to 15% by weight based on the total weight of the composition. As used herein, the term "effective amount" refers to an amount of an active ingredient that can lead to the prevention, treatment of atopic dermatitis, or alleviation of such symptoms in a person subject to the application (prescription). Such effective amounts can be determined experimentally within the range of ordinary skill in the art.

The composition for improving atopic dermatitis of the present invention may be used as a pharmaceutical composition in a specific embodiment.

The pharmaceutical composition of the present invention includes oral formulations (tablets, suspensions, granules, emulsions, capsules, syrups, etc.), parenteral formulations (sterile), in addition to pharmaceutically acceptable carrier placental extracts, as an active ingredient. Aqueous or oily suspensions for injection), topical formulations (solutions, creams, ointments, gels, lotions, patches) and the like. Preferably it is a topical formulation.

As used herein, "pharmaceutically acceptable" means that the subject of application (prescription) does not have more toxicity (adequately low toxicity) to which the subject of application (prescription) is adaptable without inhibiting the activity of the active ingredient.

Examples of pharmaceutically acceptable carriers include lactose, glucose, sucrose, starch (such as corn starch, potato starch, etc.), cellulose, derivatives thereof (such as sodium carboxymethyl cellulose, ethylcellulose, etc.) malt, gelatin, talc, solids Lubricants (e.g. stearic acid, magnesium stearate, etc.), calcium sulfate, vegetable oils (e.g. peanut oil, cottonseed oil, sesame oil, olive oil, etc.), polyols (e.g. propylene glycol, glycerin, etc.), alginic acid, emulsifiers (e.g. TWEENS), wetting agents (e.g. Sodium lauryl sulfate), colorants, flavoring agents, tableting agents, stabilizers, antioxidants, preservatives, water, saline, phosphate buffer solutions and the like. Such a carrier may be used by selecting one or more appropriate ones according to the formulation of the pharmaceutical composition of the present invention.

Excipients may be selected and used according to the formulation of the pharmaceutical composition of the present invention, for example, when the pharmaceutical composition of the present invention is prepared with an aqueous suspending agent, suitable excipients are sodium carboxymethyl cellulose, methyl cellulose, hydropropylmethylcellulose And suspending agents and dispersing agents such as sodium alginate and polyvinylpyrrolidone. Suitable excipients when prepared as injections include Ringer's solution, isotonic sodium chloride, and the like.

The pharmaceutical composition of the present invention may be administered orally or parenterally, preferably when administered topically.

The daily dosage of the pharmaceutical composition of the present invention is usually 0.001 ~ 150 mg / kg body weight range, it can be administered once or divided into several times. However, since the dosage of the pharmaceutical composition of the present invention is determined in view of various related factors such as the route of administration, the age, sex, weight of the patient, and the severity of the patient, the dosage may limit the scope of the present invention in any aspect. It should not be understood as.

The atopy improvement composition of this invention can be grasped | ascertained as a cosmetic composition in a specific aspect.

Cosmetic compositions of the present invention can be prepared in a variety of forms, including emulsions, lotions, creams (oil-in-water, water-in-oil, multiphase), solutions, suspensions (injury and water-based), anhydrous products (oils and glycols) , Gels, masks, packs, powders and the like formulation.

The cosmetic composition of the present invention may include an acceptable carrier in the cosmetic preparation in addition to the pig placenta extract.

As used herein, "acceptable carrier in cosmetic formulation" means a known or used cosmetic or composition that can be included in cosmetic formulations or a compound or composition that will be developed in the future, such that toxicity, instability or irritation is greater than the body can adapt to in contact with skin. Say that there is no.

Examples of the carrier include alcohols, oils, surfactants, fatty acids, silicone oils, wetting agents, moisturizers, viscosity modifiers, emulsions, preservatives, stabilizers, sunscreens, colorants, fragrances and the like. Such alcohols, oils, surfactants, fatty acids, silicone oils, wetting agents, moisturizers, viscosity modifiers, emulsions, preservatives, stabilizers, sunscreens, colorants, compounds / compositions that can be used as fragrances and the like are already known in the art. Those skilled in the art can select and use appropriate materials / compositions as appropriate.

The carrier may comprise from about 1% to about 99.99% by weight, preferably from about 40% to about 99.99% by weight of the composition based on the total weight of the cosmetic composition of the present invention.

However, since the ratio will vary depending on the formulation as described above in which the cosmetic composition of the present invention is prepared and its specific application site (face, neck, etc.) or its preferred application amount, the ratio is in any aspect to the present invention. It should not be understood as limiting the scope of.

In addition, the composition for atopy improvement of this invention can be grasped | ascertained as a soap composition in a specific aspect.

When the composition of the present invention is understood as a soap composition, the soap composition of the present invention may be prepared by including a pig placenta extract which is an active ingredient on a soap base, and prepared as an additive including a skin moisturizer, an emulsifier, a hard water softener, and the like. Can be.

As the soap base material, vegetable oils such as palm oil, palm oil, soybean oil, perm oil, olive oil, palm kernels, or animal oils such as tallow, pork, sunny and fish oils can be used, and the skin moisturizing agent is glycerin, erythritol and polyethylene glycol. , Propylene glycol, butylene glycol, pentylene glycol, hexyl glycol, isopropyl myristate, silicone derivatives, aloe vera, sorbitol and the like can be used, the emulsifiers include natural oils, waxes, fatty alcohols, hydrocarbons, natural plants Extracts and the like may be used, and tetrasodium idieti may be used as the water softener.

The soap composition of the present invention may further include an antimicrobial agent, a dispersant, a foam inhibitor, a solvent, a scale inhibitor, a corrosion inhibitor, a perfume, a pigment, a metal ion sequestrant, an antioxidant, a preservative, and the like as an additive.

In the soap composition of the present invention, the soap base or additives may be included in an amount generally used in the art, and the soap base is generally added in an amount of 99.999 wt% to 50 wt% based on the total weight of the soap composition. The additive may be added in an amount of 1% to 20% by weight.

As described above, according to the present invention, there is provided a composition for improving atopic dermatitis using pig placenta.

Hereinafter will be described with reference to Examples and Experimental Examples of the present invention. However, the scope of the present invention is not limited by these examples and experimental examples.

EXAMPLES Preparation of Porcine Placenta Extract

Example 1 Preparation of Porcine Placenta Extract

Washing solution was added to 100 g of lyophilized pig placenta and washed 4 to 5 times. After washing, 400 ml of a hydration solution (50 mM Tris-Cl (pH7.5) containing 1 mM EDTA, 1 mM 2-mercaptoethanol) was added, and the placenta was crushed using an ultrasonic cell grinder in an ice bath for 5 minutes (10 seconds on). , Repeat 10 seconds off). The filtrate was collected by filtration with four layers of guaze, and the filtrate was centrifuged at 700 rpm for 5 minutes to recover the supernatant first. Then, the recovered supernatant was added to Cetriprep YM-50 (50,000 NMWL) and 3,000 rpm, 90 Centrifugation in minutes gave 130 ml.

Example 2 Preparation of Hexane Fraction Extract of Porcine Placenta Extract with Ethanol

The washed placenta was lyophilized to make the pig placenta in powder form. 50 g of powdered placenta was added to 3 L of 80% ethanol, stirred at room temperature for about a day, and filtered with a vacuum pump to obtain a primary permeate. Then, the placenta on the filter paper was collected, and 2L of 80% ethanol was added thereto to obtain a second penetrant. Then, the placenta on the filter paper was collected and the third penetrant was again obtained with 2L of 80% ethanol. The primary, secondary and tertiary infiltrations thus obtained were mixed and the mixture was concentrated using a rotary concentrator and lyophilized to obtain 4.25 g of pig placenta crude extract.

The crude pig placenta crude extract was partitioned between hexane (Hexane) and ethyl acetate (EtOAC). 500 ml of distilled water, 500 ml of hexane and 4 g of crude extract were mixed in a separatory funnel, and left to stand for 8 hours, and the mixture was partitioned into a water layer and a hexane layer. The hexane layer was collected and lyophilized to obtain 0.58 g of a pig placenta extract in powder form.

Example 3 Preparation of Ethyl Acetate Fraction Extract of Porcine Placenta Extract with Ethanol

500 ml of ethyl acetate was added to the water layer remaining in the separatory funnel in <Example 2>, and the mixture was left for 8 hours or more and partitioned into an aqueous layer and an ethyl acetate layer. Ethyl acetate layer was collected and lyophilized to obtain 0.68 g of powdery placenta extract.

Experimental Example Confirmation of Atopic Dermatitis Improvement Effect

Experimental Example 1 Inhibitory Effects of Inflammatory Chemokines MDC and TARC

Using HaCaT cells, which are human keratinocyte cell lines, it was tested whether the extract of the above example had an inhibitory effect on the expression of inflammatory chemokines, MDC and TARC.

HaCaT cells, 10% fetal bovine serum (FBS) and 100 unit / ㎖ penicillin-streptomycin using (Gibco BRL) DMEM (Dulbecco's Modified Eagle's Medium, Gibco BRL) that contains a cell culture medium, 37 ℃, 5% CO ₂ Cultured in an incubator to maintain.

After dispensing HaCaT cells (1 ㎖ 10 ⁶ cells / mL) in a 60 φ dish and incubating for 18 hours, each extract (200 ㎍ / mL) and hIFN-γ (final concentration 10 ng / mL) were treated simultaneously. After incubation, total RNA extraction was isolated using TRI-reagent (MRC). The cells were homogenized by addition of TRI-reagent, and then centrifuged by addition of chloroform. Equivalent amount of isopropanol was added to the supernatant to centrifuge to precipitate RNA, washed with 75% DEPC treated ethanol, dried and dissolved in DEPC treated distilled water. RNA was quantified by measuring absorbance at 260 nm, and RNA having a value in the ratio of A260 / A280 nm in the range of 1.7 ^to 1.9 was used for the experiment. All experiments were done under RNase-free conditions.

1 μg of total RNA was mixed with oligo (dT) 18 primer, dNTP (0.5 μM), 1 unit RNase inhibitor and M-MuLV reverse transcriptase (2 U) at 70 ° C for 5 minutes, 25 ° C for 5 minutes, 37 ° C for 60 minutes, and The reaction was stopped by heating at 70 ° C. for 15 minutes. Polymerase chain reaction (PCR) was performed using 1 μl cDNA, 4 μM of 5 'and 3' primers, 10x buffer (10 mM Tris-HCl, pH 8.3, to amplify MDC, TARC, and β-Actin from synthesized cDNA. Mix 50 mM KCl, 0.1% Triton X-100), 250 μM dNTP, 25 mM MgCl2, 1 unit Taq polymerase (Promega, USA), adjust the total to 25 μl with distilled water, and PCR using Perkin-Elmer Thermal Cycler. Was carried out.

Primer sequences used for PCR are shown in Table 1 below.

Primer sequence primer order SEQ ID NO: MDC forward primer 5'-GCATGGCTCGCCTACAGACT-3 ' One MDC reverse primer 5'-GCAGGGAGGGAGGCAGAGGA-3 ' 2 TARC forward primer 5'-ATGGCCCCACTGAAGATGCT-3 ' 3 TARC reverse primer 5'-TGAACACCAACGGTGGAGGT-3 ' 4 β-actin forward primer 5'-ATGGGTCAGAAGGATT-CCTATG-3 ' 5 β-actin reverse primer 5'-CAGCTCGTAGCTC-TTCTCCA-3 ' 6

The PCR conditions were 94 ℃ / 45 seconds, 55 ^~ 60 ℃ / 45 seconds, 72 ℃ / 60 seconds, 35 times, the product produced by PCR is subjected to electrophoresis on 1.5% agarose gel and stained with ethidium bromide I identified a specific band.

The results are shown in FIGS. 1 and 2.

Referring to <FIG. 1> and <FIG. 2>, it can be seen that all of the extracts of the example have an inhibitory effect on MDC and TARC fermentation. In particular, the extract of Example 1 had the highest inhibitory effect on MDC and TARC fermentation.

Experimental Example 2 Clinical Evaluation of Atopic Dermatitis Patients

First, the cosmetic composition was prepared by using the extract of Example 1, which was shown to be the most effective above, using the ingredients and contents of Table 2 below.

Cosmetic composition ingredients and contents ingredient content(%) Purified water Remaining amount 1,3-butylene glycol 4.00 glycerin 5.00 EDTA-2Na (Disodium EDTA) 0.01 Triethanolamine 0.01 Montanox 60 (Polysorbate 60) 0.30 Montanov (Catearyl Stearate / PEG-100 Stearate) 1.50 Napol 1822B (Nafol 1822B (Behenyl Alcohol)) 1.30 DC200 (DC200 (100cs) / (Dimethicone)) 0.50 Miglyol 8810 (Butylene Glycol dicaprylate / Dicaprate) 7.00 Medicine 0.20

Clinical evaluation was performed by Ellid Co., Ltd. (Seongnam, Gyeonggi-do). Twelve male and female adults and children suffering from atopic dermatitis, which were determined to be suitable for the experiment, were selected to take an appropriate amount of the cosmetic composition twice a day for 8 weeks to be applied to the whole body (the lesion site was applied from time to time).

The atopy improvement effect was evaluated by EASI index. The EASI index is graded by the dermatologist in four stages: erythema, edema, stiffness, papules, scratches, and thyroiditis in the head, neck, upper limbs, torso and lower limbs of atopic dermatitis patients. The higher the value, the more severe the atopic condition. The lower the value, the better the skin improvement effect.

The results are shown in Figure 3 as the average value of the index of EASI, three subjects were selected and the degree of improvement is shown in the photograph in Figure 4.

3 and 4 show that the cosmetic composition has an atopic dermatitis improving effect. For reference, no particular adverse reaction was observed during the test period, and thus, the extract of <Example 1> included in the cosmetic composition was determined to be safe.

1 is a result showing that the pig placenta extract of the present invention has an MDC fermentation inhibitory effect. P is the extract by ultrasound, 1 is the ethyl acetate fraction extract of pig placenta extract by ethanol and 2 is the hexane fraction extract of pig placenta extract by ethanol.

Figure 2 is a result showing that the pig placenta extract of the present invention has a TARC fermentation inhibitory effect. P is the extract by ultrasound, 1 is the ethyl acetate fraction extract of pig placenta extract by ethanol and 2 is the hexane fraction extract of pig placenta extract by ethanol.

Figure 3 shows the results of clinical trials for atopic dermatitis patients as the average value of the index of EASI.

Figure 4 shows the results of the clinical trials for atopic dermatitis patients in three subject photographs.

<110> Jeju Hitech <120> Composition for Improving a Atopy Epidermal Inflammation Using          Pig placenta <160> 6 <170> KopatentIn 1.71 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Sense primer <400> 1 gcatggctcg cctacagact 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Anti-sense primer <400> 2 gcagggaggg aggcagagga 20 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Sense primer <400> 3 atggccccac tgaagatgct 20 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Anti-sense primer <400> 4 tgaacaccaa cggtggaggt 20 <210> 5 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> Sense primer <400> 5 atgggtcaga aggattccta tg 22 <210> 6 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Anti-sense primer <400> 6 cagctcgtag ctcttctcca 20  

Claims (8)

The composition for improving atopic dermatitis, comprising the pig placenta extract selected from the following (a), (b) and (c) as an active ingredient (a) porcine placenta extract by ultrasound, (b) hexane fraction extract of pig placenta extract with water, ethanol or a mixed solvent thereof, and (c) ethyl acetate fraction extract of pig placenta extract with water, ethanol or a mixed solvent thereof The method of claim 1, The atopic dermatitis is atopic dermatitis, pediatric atopic dermatitis, adult atopic dermatitis and maternal atopic dermatitis, characterized in that the composition for improving atopic dermatitis. The method of claim 1, The composition is a composition for improving atopic dermatitis, characterized in that the pharmaceutical composition. The method of claim 1, The composition is a composition for improving atopic dermatitis, characterized in that the cosmetic composition. The method of claim 1, The composition is a composition for improving atopic dermatitis, characterized in that the soap composition. The method of claim 1, Porcine placenta extract by the ultrasonic wave is a composition for improving atopic dermatitis, characterized in that one of the extract of (a) to (d) (a) an extract obtained by crushing the placenta by adding water, ethanol or a mixed solvent thereof to lyophilized and powdered porcine placenta powder and radiating ultrasonic waves, (b) water, ethanol or a mixed solvent of lyophilized and powdered swine placenta powder, and the extract of the powder state in which the solvent is removed from the crushed product after crushing the placenta by radiating ultrasonic waves, (c) extract of the supernatant obtained by adding water, ethanol or a mixed solvent thereof to the lyophilized and powdered pig placenta powder, and radiating the placenta by radiating ultrasonic waves to centrifuge the crushed material to discard the precipitate; (d) powdered extract of the supernatant obtained by adding water, ethanol or a mixed solvent thereof to the lyophilized and powdered porcine placenta powder and radiating the placenta by radiating ultrasonic waves, and then centrifuging the crushed matter, (e) Water, ethanol or a mixed solvent thereof was added to the lyophilized and powdered pig placenta powder, and the ultrasonic place was crushed to break up the placenta, filtered to remove the extraction residue, and the filtrate was centrifuged to discard the precipitate. Extract of supernatant, and (f) Water, ethanol or a mixed solvent thereof was added to the lyophilized and powdered porcine placenta powder, the ultrasonic place was radiated to break the placenta, filtered to remove the extraction residue, and the filtrate was centrifuged to take a supernatant. Powdered product from which the solvent was removed from the supernatant. The method of claim 1, The hexane fraction extract of the pig placenta extract by the water, ethanol or a mixed solvent thereof is one of the extracts of the following (a) and (b) composition for improving atopic dermatitis (a) fraction extract of the hexane layer obtained by adding water, ethanol or a mixed solvent thereof to the lyophilized and powdered pig placenta powder to remove the extraction solvent and then adding water and hexane to the crude extract; And (b) Fraction from hexane layer fraction extract obtained by adding water, ethanol or a mixed solvent to lyophilized and powdered porcine placenta powder to remove the extraction solvent and adding water and hexane to the crude extract. Fraction extract obtained by removing hexane as a solvent. The method of claim 1, Ethyl acetate fraction extract of pig placenta extract by water, ethanol or a mixed solvent thereof is one of the extracts of the following (a) and (b) composition for improving atopic dermatitis (a) Fractional extract of ethyl acetate layer obtained by adding water, ethanol or a mixed solvent thereof to lyophilized and powdered porcine placenta powder, and then extracting the extraction solvent and adding water and ethyl acetate to the crude extract. , (b) Fractional extract of ethyl acetate layer obtained by adding water, ethanol or a mixed solvent thereof to lyophilized and powdered porcine placenta powder to remove the extraction solvent, and adding water and ethyl acetate to the crude extract. Fraction extract obtained by removing ethyl acetate as a fractional solvent in (c) Water, ethanol or a mixed solvent thereof was extracted and extracted from the lyophilized and powdered pig placenta powder, and then the extraction solvent was removed. To the obtained crude extract, ethyl acetate was added to the water layer obtained by standing with water and hexane. Fraction extract of ethyl acetate layer obtained by standing still, and (d) Water, ethanol or a mixed solvent thereof is extracted and extracted by adding lyophilized and powdered porcine placenta powder to the crude extract, and ethyl acetate is added to the water layer obtained by adding water and hexane and standing still. Fractional extract obtained by removing ethyl acetate from the fractional extract of the ethyl acetate layer obtained by.

Images